Indicate Solutions is dedicated to developing handheld economic single use rapid nucleic acid tests (NAT) in order to revolutionise current diagnostic practices. Imagine a scenario where cancer patients can monitor their response to treatment and the progress of their disease in the comfort of their own home, or at the pharmacy or in their local doctors sugery. Imagine being able to diagnose HIV or Ebola immidiately in remote villages without the need for electricity or other infrastructure.

This is our vision.

In order to obtain proof-of-principle for the Indicate device technology the initial indication we are focusing on is EGFR mutation testing in the blood of lung cancer patients. Specificially we are focusing on the most common diagnostic mutation (L858R) and a mutation (T790M) that has been approved for treatment change in lung cancer patients. We will extend these indications to other cancers including KRAS mutations in colorectal cancer, BRAF mutations in melanoma, ALK, ROS1, FGFR, VEGFR, JAK, BRCA, MSI and Bcl2 amongst others

Having tested these mutations in the laboratory succesfully we are currently prototyping the technology as a fully functional detection device based on a control unit/cartridge format (below). This phase in the development of the final handheld integrated device, will allow us to optmise the technology and significantly reduce the technical risk involved.

Our aim is to have the prototype fully functional and verified within the next 24 months subject to funding.

In parallel we are developing specific probes and technology for HIV testing.